ArticleDiscover oncology2025
Steroid resistant bullous pemphigoid induced by pembrolizumab in a patient with metastatic lung adenocarcinoma: case report and review of the literature.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPembrolizumab, a PD-1 inhibitor, is widely used for treating advanced cancers, including metastatic non-small cell lung cancer (NSCLC). However, its use can lead to immune-related adverse events (IRAEs), including cutaneous manifestations such as bullous pemphigoid (BP). CASE PRESENTATION: We report a case of a 69-year-old gentleman with metastatic left lung adenocarcinoma who developed steroid-resistant BP following pembrolizumab treatment. Initially diagnosed in August 2020 and treated with surgery, chemotherapy, and an IL-1B inhibitor, the patient showed no evidence of recurrence until November 2021. Subsequent metastases were treated with surgery, stereotactic radiosurgery (SRS), and whole-brain radiotherapy (WBRT). In November 2022, pembrolizumab was initiated. Following three sessions, the patient developed facial skin edema, muscle weakness, and later, a rash with multiple bullae. Despite discontinuing pembrolizumab and starting high-dose topical steroids and oral prednisone, the BP proved to be refractory. The patient was switched to methotrexate with marked improvement but not complete resolution. Continued management included reduced pembrolizumab doses and additional SRS, eventually achieving control over both the metastatic disease and BP. DISCUSSION: This case highlights a case of severe and steroid-resistant nature of pembrolizumab-induced BP, necessitating alternative immunosuppressive therapy. The complexity of managing IRAEs in patients undergoing ICI therapy underscores the importance of a multidisciplinary approach and vigilant monitoring.
conclusionThis report adds to the growing body of evidence on IRAEs, particularly BP induced by ICIs, and suggests that methotrexate can be an effective treatment for steroid-resistant BP in the context of cancer immunotherapy. Further research is needed to better understand the mechanisms and optimal management strategies for ICI-induced BP.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.